Caution in interpretation of abnormal carbon monoxide diffusion capacity in covid-19 patients
| Field | Value | Language |
| dc.contributor.author | Chapman, D.G. | en |
| dc.contributor.author | Badal, T. | en |
| dc.contributor.author | King, G.G. | en |
| dc.contributor.author | Thamrin, C. | en |
| dc.date.accessioned | 2021-06-02T04:55:24Z | |
| dc.date.available | 2021-06-02T04:55:24Z | |
| dc.date.issued | 2021 | |
| dc.identifier.uri | https://hdl.handle.net/2123/25315 | |
| dc.language.iso | en | en |
| dc.rights | Copyright All Rights Reserved | en |
| dc.subject | COVID-19 | en |
| dc.subject | Coronavirus | en |
| dc.title | Caution in interpretation of abnormal carbon monoxide diffusion capacity in covid-19 patients | en |
| dc.type | Article, Letter | en |
| dc.identifier.doi | 10.1183/13993003.03263-2020 | |
| dc.relation.other | AstraZeneca GlaxoSmithKline, GSK Boehringer Ingelheim National Health and Medical Research Council, NHMRC GlaxoSmithKline Australia, GSK | en |
| usyd.faculty | SeS faculties schools::Faculty of Medicine and Health | en |
Associated file/s
There are no files associated with this item.
Associated collections